Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) FCF Margin: 2020-2023

Historic FCF Margin for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to -165.35%.

  • Candel Therapeutics' FCF Margin rose 2293465.00% to -165.35% in Q4 2023 from the same period last year, while for Dec 2023 it was -1,337.23%, marking a year-over-year increase of 2504665.00%. This contributed to the annual value of -1,293.73% for FY2024, which is 4349.00% up from last year.
  • As of Q4 2023, Candel Therapeutics' FCF Margin stood at -165.35%, which was down 112.41% from 1,331.99% recorded in Q3 2023.
  • Candel Therapeutics' FCF Margin's 5-year high stood at 1,799.18% during Q1 2023, with a 5-year trough of -30,964.52% in Q3 2022.
  • Its 3-year average for FCF Margin is -14,918.04%, with a median of -19,927.42% in 2021.
  • As far as peak fluctuations go, Candel Therapeutics' FCF Margin crashed by 1,413,548bps in 2021, and later spiked by 3,229,650bps in 2023.
  • Quarterly analysis of 4 years shows Candel Therapeutics' FCF Margin stood at -12,480.65% in 2020, then crashed by 604,194bps to -18,522.58% in 2021, then slumped by 457,742bps to -23,100.00% in 2022, then soared by 2,293,465bps to -165.35% in 2023.
  • Its FCF Margin was -165.35% in Q4 2023, compared to 1,331.99% in Q3 2023 and 1,143.48% in Q2 2023.